drug
Syfovre
Marketedupdated 3mo agoby $APLS Apellis Pharmaceuticals, Inc.
Approvedcommunity read0 votes
indications
investigational
AMD
all catalysts(0)
nothing on the calendar yet
Trials studying Syfovre
- phase2Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- phase3An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
- phase3Pegcetacoplan Long Term Safety and Efficacy Extension Study
- phase2A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
- phase2Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
- phase1A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
- phase3An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- phase2A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 25, 2026
74 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- Dec 14, 2038formulationUS 12290566
- Dec 14, 2038formulationUS 12458695
- Dec 9, 2038formulationUS 11844841
- Apr 9, 2038formulationUS 11040107
- Feb 22, 2037method-of-use (U-3828)US 11903994
- Oct 7, 2036method-of-use (U-4394)US 12528836
- Nov 15, 2033compositionUS 10035822
- Nov 15, 2033compositionUS 10035822
- Nov 15, 2033compositionUS 10875893
- Nov 15, 2033compositionUS 10875893
- Nov 15, 2033compositionUS 11292815
- Nov 15, 2033compositionUS 11292815
- Aug 2, 2033compositionUS 10125171
- Aug 2, 2033compositionUS 10125171
- Jan 13, 2033compositionUS 11661441
- Jan 13, 2033compositionUS 11661441
- Dec 4, 2027compositionUS 78883231.3y
- Dec 4, 2027compositionUS 78883231.3y
- Dec 4, 2027compositionUS 79895891.3y
- Dec 4, 2027compositionUS 79895891.3y
- Nov 18, 2027compositionUS 91693071.3y
- Nov 18, 2027compositionUS 91693071.3y
- Apr 7, 2027method-of-use (U-3542)US 8168584238d
- Oct 25, 2026method-of-use (U-3540)US 905607674d
FDA exclusivities (6)
- Jul 28, 2028I-972Indication (3y)2.0y
- May 14, 2028ODE-351Orphan Drug (7y)1.8y
- May 14, 2026NCENew Chemical Entity (5y)
- May 14, 2026NCENew Chemical Entity (5y)
- Feb 22, 2026NPNP
- Feb 8, 2026M-288Method (3y)
News(3)
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 17h ago
- Biogen shifts M&A strategy as Apellis acquisition pushes revenue above analyst expectationsBiogen officially began reporting revenue from the $5.6 billion acquisition of Apellis in the second quarter, shaking up analysts’ consensus estimates and leading to a beat.biospace · 13d ago
- Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 7mo ago
Data sources
last refreshed 50m ago
Found something off?
comments(0)
5-min edit window · permanent after that